[7]
Sharma A, Zhao X, Hammill BG, et al. Trends in noncardiovascular comorbidities among patients hospitalized for heart failure: Insights from the get with the guidelines-heart failure registry. Circ Heart Fail 2018; 11(6): e004646.
[9]
Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: A report of the American college of cardiology/american heart association joint committee on clinical practice guidelines. J Am Coll Cardiol 2022; 79(17): e263-421.
[66]
Butler J, Anker SD, Lund LH, et al. Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial. 2022; 43: 4362-73.
[69]
Ampadu J, Morley JE. Heart failure and cognitive dysfunction. Int J Cardiol 2015; 178: 12-23.
[82]
McMurray J, Packer M, Desai A, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014; 371(11): 993-1004.
[84]
McMurray JJV, Krum H, Abraham WT, et al. Aliskiren, enalapril, or aliskiren and enalapril in heart failure. N Engl J Med 2016; 374: 1521-32.
[85]
Pagel P, Tawil J, Boettcher B, et al. Heart failure with preserved ejection fraction: A comprehensive review and update of diagnosis, pathophysiology, treatment, and perioperative implications. J Cardiothorac Vasc Anesth 2021; 35(6): 1839-59.
[91]
Eid PS, Ibrahim DA, Zayan AH, et al. Comparative effects of furosemide and other diuretics in the treatment of heart failure: A systematic review and combined meta-analysis of randomized controlled trials. Heart Fail Rev 2021; 26: 127-36.
[95]
Przybylowski P, Wasilewski G, Golabek K, et al. Absolute and functional iron deficiency is a common finding in patients with heart failure and after heart transplantation. Transplant Proc 2016; 48: 173-6.
[96]
Jankowska EA, Tkaczyszyn M, Suchocki T, et al. Effects of intravenous iron therapy in iron-deficient patients with systolic heart failure: A meta-analysis of randomized controlled trials. Eur J Heart Fail 2016; 18(7): 786-95.
[98]
Mei Z, Chen J, Luo S, et al. Comparative efficacy of intravenous and oral iron supplements for the treatment of iron deficiency in patients with heart failure: A network meta-analysis of randomized controlled trials. Pharmacol Res 2022; 182: 106345.
[103]
Nassif ME, Windsor SL, Borlaug BA, et al. The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: A multicenter randomized trial. Nat Med 2021; 27: 1954-60.
[104]
Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 2020; 383: 1413-24.
[105]
McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 2019; 381: 1995-2008.
[108]
Giugliano D, Longo M, Signoriello S, et al. The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: A network meta-analysis of 23 CVOTs. Cardiovasc Diabetol 2022; 21: 42.
[112]
Kappel BAA, Marx N, Federici M. Oral hypoglycemic agents and the heart failure conundrum: Lessons from and for outcome trials. Nutr Metab Cardiovasc Dis 2015; 25: 697-705.
[114]
Lehrke M, Marx N. Diabetes mellitus and heart failure. Eur Cardiol 2017; 130: S40-50.
[131]
Beezer J, Al Hatrushi M, Husband A, et al. Polypharmacy definition and prevalence in heart failure: A systematic review. Heart Fail Rev 2022; 27: 465-92.
[139]
Linzer D. poLCA: An R package for polytomous variable latent class analysis. J Stat Softw 2011; 42(10): 1-29.
[140]
Gulea C, Zakeri R, Quint JK. Model-based comorbidity clusters in patients with heart failure: Association with clinical outcomes and healthcare utilization. BMC Med 2021; 19: 9.